港股異動 | 乳業股普遍強勢 蒙牛乳業、澳優皆漲超4%
格隆匯10月20日丨港股乳業股普遍強勢,蒙牛乳業漲4.8%,澳優漲4.5%,中國飛鶴、中國聖牧均有漲幅。
日前2020中國奶業大會召開,蒙牛盧敏放提出“乳業強國”五大倡議。他提出,抓住疫後乳品消費升級的歷史性機遇,拿出更高品質的產品與服務;繼承發揮“抗疫精神”,進一步提升供應鏈穩定性和產業鏈競爭力,將“奶瓶子”牢牢抓在自己手中。
數據顯示,2019年全國奶類產量3297.6萬噸,同比增長3.8%,居世界第四位,且人均年消費生鮮乳達到35.8公斤,比2015年增長4.9公斤。2020年上半年澳優、飛鶴、貝因美三家企業均實現了營收、淨利雙增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.